Patents by Inventor Holger Wallmeier

Holger Wallmeier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230159610
    Abstract: The present invention relates to the field of immunology, in particular, to the field of modulation of immune responses, in particular, suppression of immune responses and/or induction of tolerance. It provides a tregitope (regulatory T cell activating epitope) carrying polypeptide based on sequences derived from the Fc part of human IgG, wherein said TCP comprises at least one tregitope heterologous to human IgG that is located within at least one of three specific sequence frames. The invention provides such polypeptides for multiple purposes, e.g., in monomeric or dimeric form, wherein both are optionally be linked to an agent, e.g., to which an immune response is to be modulated or suppressed, or co-administered to such an agent, or for use as a stand-alone therapeutic. Nucleic acids encoding the TCP of the invention, pharmaceutic compositions and uses of said TCP are also provided.
    Type: Application
    Filed: March 26, 2021
    Publication date: May 25, 2023
    Inventors: Steffen KISTNER, Jens DAUFENBACH, Christopher UNGERER, Peter HERBENER, Holger WALLMEIER
  • Publication number: 20180312905
    Abstract: The current invention relates to a microvesicle based method of detecting avian necrotic enteritis as well as to new markers which have been identified as suitable for detection of avian necrotic enteritis and/or avian infection by Clostridium perfringens.
    Type: Application
    Filed: February 19, 2016
    Publication date: November 1, 2018
    Applicant: Evonik Degussa GmbH
    Inventors: Emeka-Ignatius IGWE, Holger WALLMEIER, Stefan PELZER, Monika FLÜGEL, Thomas BEKEL
  • Patent number: 9995733
    Abstract: Provided are methods of screening to identify molecules capable of binding to CD4 and capable of activating CD4+CD25+ regulatory T cells. Further provided are antibodies and antibody fragments capable of activating CD4+CD25+ regulatory T cells and methods and uses involving the antibodies and fragments thereof.
    Type: Grant
    Filed: May 30, 2012
    Date of Patent: June 12, 2018
    Assignee: BIOTEST AG
    Inventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Benjamin Daelken, André Engling, Chantal Zuber, Niklas Czeloth, Holger Wallmeier, Kirsten Völp, Gregor Schulz
  • Publication number: 20130004513
    Abstract: Provided are methods of screening to identify molecules capable of binding to CD4 and capable of activating CD4+CD25+ regulatory T cells. Further provided are antibodies and antibody fragments capable of activating CD4+CD25+ regulatory T cells and methods and uses involving the antibodies and fragments thereof.
    Type: Application
    Filed: May 30, 2012
    Publication date: January 3, 2013
    Inventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Benjamin Daelken, André Engling, Chantal Zuber, Niklas Czeloth, Holger Wallmeier, Kirsten Völp, Gregor Schulz
  • Patent number: 6127346
    Abstract: Novel oligonucleotide analogs of the formula [I] are described, ##STR1## in which A, B, D, G, L, P, Q, Q', R.sup.5, R.sup.6, X, Y, Z and n are as defined in the description, which have useful physical, biological and pharmacological properties, as well as a process for their preparation. Their application relates to use as inhibitors of gene expression (antisense oligonucleotides, ribozymes, sense oligonucleotides and triplex-forming oligonucleotides), as probes for the detection of nucleic acids and as auxiliaries in molecular biology.
    Type: Grant
    Filed: November 20, 1998
    Date of Patent: October 3, 2000
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Anuschirwan Peyman, Eugen Uhlmann, Gerhard Breipohl, Holger Wallmeier
  • Patent number: 5874553
    Abstract: Novel oligonucleotide analogs of the formula (I) are described, ##STR1## in which A, B, D, G, L, P, Q, Q', R.sup.5, R.sup.6, X, Y, Z and n are as defined in the description, which have useful physical, biological and pharmacological properties, as well as a process for their preparation. Their application relates to use as inhibitors of gene expression (antisense oligonucleotides, ribozymes, sense oligonucleotides and triplex-forming oligonucleotides), as probes for the detection of nucleic acids and as auxiliaries in molecular biology.
    Type: Grant
    Filed: March 11, 1996
    Date of Patent: February 23, 1999
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Anuschirwan Peyman, Eugen Uhlmann, Gerhard Breipohl, Holger Wallmeier
  • Patent number: 5629288
    Abstract: Lipopeptide derivatives of the formula I ##STR1## with R.sup.1 equal to OH or NH.sub.2 and R.sup.2 a C.sub.8 -C.sub.22 -acyl radical, pharmaceutical products which are effective for bacterial infections and contain such lipopeptide derivatives, process for preparing the lipopeptide derivatives and the pharmaceutical products, and the use of the lipopeptide derivatives for controlling bacterial infections are described.
    Type: Grant
    Filed: March 28, 1995
    Date of Patent: May 13, 1997
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Rudolf Lattrell, Theodor Wollmann, Holger Wallmeier, Peter Hammann, Dieter Isert
  • Patent number: 5426036
    Abstract: The tendamistat gene can be used for the construction of fused genes with which fusion proteins are expressed and excreted in Streptomycetes host cells. The tendamistat portion can be modified, in particular it can be C-terminal shortened. When a gene for a shortened proinsulin in which the insulin B chain is linked to the A chain only via Lys or Lys-Lys is coupled to the tendamistat gene, this gene construction is introduced into an expression vector, and the latter is used to transform a Streptomycetes host cell, there is expression and secretion of the corresponding fusion protein. The fusion protein can easily be cleaved to give insulin precursors because of correctly established disulfide bonds. Genetic structures which code for the signal sequence and about the first ten amino acids of tendamistat as well as a desired protein are expressed in streptomyces host cells with a high yield, and the fusion proteins are secreted into the medium.
    Type: Grant
    Filed: March 12, 1993
    Date of Patent: June 20, 1995
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Klaus-Peter Koller, Gunther Riess, Eugen Uhlmann, Holger Wallmeier